The Filing Desk

Fennec Pharmaceuticals

FENC · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

FENC · Last close · November 19, 2026
$13.45
Value Fennec Pharmaceuticals yourself

Fennec Pharmaceuticals' revenue fell 6.1% to $45 million in fiscal 2025. Its operating margin was −14.1%, down from 5.4% a year earlier. The diluted share count rose 4.7%.

FENNEC PHARMACEUTICALS INC. Latest fiscal year ended December 31, 2025 10-K filed March 27, 2026 · 0001104659-26-036182 Updated
Revenue
$45M
6.1%
Operating margin
−14.1%
19.5 pts
Net income
−$10M
 
Free cash flow
—
 
Return on equity
−65.8%
 
Market cap
$512M
Nov 19 close
P/E
—
Over 200x

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Piotroski F-score for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Fennec Pharmaceuticals does

Fennec Pharmaceuticals is a drug company with one product, PEDMARK. PEDMARK is the only FDA-approved treatment meant to reduce the risk of hearing loss (ototoxicity) caused by the chemotherapy drug cisplatin in children one month old and older who have localized, non-metastatic solid tumors. The company is incorporated in British Columbia and has a U.S. subsidiary in Delaware.

Fennec earns revenue by selling PEDMARK in the United States. For sales outside the U.S., it says it needs partners, and it would need more financing to seek approval and sell PEDMARK abroad. It says it has had limited revenue since its start.

The company calls itself a single-product company with limited commercial experience. It says it may have to run additional clinical trials for PEDMARK, which would cost money and take time.

Its biggest risks, as it describes them

  • It has a history of significant losses and limited revenue from selling its product.
  • PEDMARK is its only product, so its success depends on selling that one drug.
  • It may need more financing for approval and sales outside the U.S., and needs partners abroad.
  • It may have to run additional, costly clinical trials for PEDMARK.
From Fennec Pharmaceuticals's annual report on Form 10-K, filed March 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Fennec Pharmaceuticals lost money in fiscal 2025: a net loss of $10 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments2124132737
Debt incl. finance leases—253119—
Net debt (negative means net cash)—118−7—
Net debt to EBITDA—————
Debt to equity—————
Interest coverage——−3.8x0.6x−3.0x
Current ratio13.5x5.8x3.6x6.4x6.4x
Quick ratio13.5x5.7x3.3x6.2x6.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for Fennec Pharmaceuticals' filings doesn't give both for any year, so free cash flow is left out.

Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Fennec Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Fennec Pharmaceuticals shares on the open market, and 6 insiders sold $9.9 million, $2.2 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 13, 2026Marco Maria BrugheraDirectorSold plan20,000$12.00$240,000Form 4
Sep 15, 2026Marco Maria BrugheraDirectorSold plan15,545$10.29$159,958Form 4
Sep 1, 2026Rosty RaykovFormer DirectorSold plan10,000$12.11$121,100Form 4
Aug 31, 2026Pierre Sargis SayadChief Medical OfficerSold12,000$12.18$146,160Form 4
Aug 27, 2026Robert AndradeChief Financial OfficerSold plan75,000$11.78$883,500Form 4
Aug 3, 2026Rosty RaykovFormer DirectorSold plan10,000$9.58$95,800Form 4
Jul 1, 2026Rosty RaykovFormer DirectorSold plan9,599$10.41$99,926Form 4
Jun 1, 2026Rosty RaykovDirectorSold plan9,747$9.62$93,766Form 4
May 11, 2026Chris A RallisDirectorSold plan8,346$7.04$58,756Form 4
May 1, 2026Rosty RaykovDirectorSold plan10,781$6.47$69,753Form 4
Apr 1, 2026Rosty RaykovDirectorSold plan10,946$6.31$69,069Form 4
Mar 2, 2026Rosty RaykovDirectorSold plan10,079$8.36$84,260Form 4
The latest 12 of 16 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 96 of 8—
Rule of 40———
Altman Z''−25.40−10.24−4.88
Accruals ratio4.1%−76.4%4.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomeFailPassFail
Debt fell relative to assetsFailPass—
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin roseFail——
Revenue rose relative to assetsPassPassFail
F-score2 of 96 of 8—
Companies that report no gross profit are scored on the other eight.

Compare

Put Fennec Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Fennec PharmaceuticalsFY25−6.1%−14.1%————
Protagonist TherapeuticsFY25−89.4%−343.6%121.9%———Compare
SepternaFY254,174.5%−148.6%238.7%———Compare
Wave Life SciencesFY25−60.5%−504.1%−440.5%———Compare
Coherus OncologyFY2559.8%−429.5%————Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue00000—2214845
Revenue growth———————1,284.5%123.7%−6.1%
Gross profit——————120——
Research and development0256554000
Operating income−3−7−10−13−18−17−23−133−6
Net income−3−7−10−13−18−17−24−16−0−10
Diluted EPS (US$)−0.22−0.47−0.52−0.64−0.76−0.67−0.90−0.60−0.02−0.34
Diluted shares (millions)13151920242626272729
Cash flow
Cash from operations−2−4−8−9−16−14−18−1727−12
Capital expenditure——————————
Free cash flow——————————
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation1223344557
Balance sheet at fiscal year end
Cash and short-term investments4282314302124132737
Debt incl. finance leases——————253119—
Total assets4282314312227274571
Total liabilities02222730385135
Shareholders' equity42721122916−3−12−636
Margins and ratios
Gross margin——————94.4%94.1%——
Operating margin————−10,520.6%—−1,471.6%−60.1%5.4%−14.1%
Net margin————−10,652.4%—−1,544.9%−75.5%−0.9%−21.8%
Free cash flow margin——————————
Rule of 40 (growth + FCF margin)——————————
Return on capital——————————
Return on equity−135.4%−46.5%−41.1%−77.0%−88.5%−77.4%−359.2%——−65.8%
Return on assets−111.8%−43.5%−38.5%−68.9%−79.5%−64.5%−96.1%−59.6%−1.2%−16.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Fennec Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Fennec Pharmaceuticals.